Targets › PIK3CA
40 programs from 34 companies in 119 trials: 57 Phase 2, 52 Phase 1, 10 Phase 3; Oncology, Other, Metabolic and endocrine; next expected readout Nov 2026.
Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides. Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). (UniProt, P42336)
Open in Phaseline: the race on PIK3CA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Inavolisib PI3-kinase p110-alpha subunit inhibitor | PIK3CA | Phase 3 | Breast Cancer; Metastatic Breast Cancer; Metastatic Castration-Resistant Prostate Cancer; PIK3CA-Mutated Cancers … | Nov 2026 |
| Celcuity | Gedatolisib Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 3 | Breast Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer); Endometrial Cancer; TNBC - Triple-Negative Breast Cancer | Dec 2026 |
| Novartis | Alpelisib (BYL719) PI3-kinase p110-alpha subunit inhibitor | PIK3CA | Phase 3 | Breast Cancer; Advanced HER2+Breast Cancer; Breast Neoplasms; Advanced Breast Cancer … | Jan 2027 |
| Risen (Suzhou) Pharma Tech | JS105 PIK3CA inhibitor | PIK3CA | Phase 3 | Breast Cancer; Advanced Solid Tumors | Feb 2027 |
| Relay Therapeutics | Zovegalisib (RLY-2608) PIK3CA inhibitor | PIK3CA | Phase 3 | PIK3CA Mutation; PIK3CA-Related Overgrowth Spectrum (PROS) | Apr 2027 |
| Eli Lilly | Tersolisib (LY4064809/STX-478) PIK3CA inhibitor | PIK3CA | Phase 3 | Breast Neoplasms | May 2029 |
| Liling Zhang | Chidamide PI3K inhibitor | PIK3CA | Phase 2 | Newly Diagnosed Peripheral T-cell Lymphoma | Dec 2026 |
| The First Affiliated Hospital of Xiamen University | Chidamide PI3K inhibitor | PIK3CA | Phase 2 | Peripheral T Cell Lymphoma; Leukemia, Myeloid, Acute; Follicular Lymphoma; Relapsed or Refractory Acute Myeloid Leukemia | Dec 2026 |
| National Cancer Institute (NCI) | Copanlisib Hydrochloride PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor | PIK3CA, PIK3CD | Phase 2 | Advanced Lymphoma; Follicular Lymphoma; Malignant Solid Neoplasm; Advanced Malignant Solid Neoplasm … | Dec 2026 |
| The First Affiliated Hospital of Xiamen University | Duvalisib Dual phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase kinase 4 (MEK) | PIK3CA, PIK3CB, MAP2K4 | Phase 2 | Peripheral T Cell Lymphoma | Dec 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | Linperlisib PI3K inhibitor | PIK3CA, PIK3CB, PIK3D | Phase 2 | Relapsed/Refractory Large B-Cell Lymphoma; Lymphoma, T-Cell | Dec 2026 |
| iOnctura | roginolisib (IOA-244) PI3K inhibitor | PIK3CA | Phase 2 | Uveal Melanoma; Non-Squamous Non-Small Cell Lung Cancer (NSCLC); Myelofibrosis (MF); Solid Tumor, Adult … | Jan 2027 |
| Peking University | linperlisib PI3K inhibitor (p110α-selective) | PIK3CA | Phase 2 | Nodal T-follicular Helper Cell Lymphoma | Jan 2027 |
| National Cancer Institute (NCI) | Taselisib (GDC-0032) PI3-kinase class I inhibitor | PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2 | Phase 2 | Advanced Lymphoma | Mar 2027 |
| MedSIR | MEN1611 Selective PI3K inhibitor with potent activity against PIK3CA catalytic subunit alpha | PIK3CA | Phase 2 | Breast Cancer | Jul 2027 |
| Christian Buske | Copanlisib PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor | PIK3CA, PIK3CD | Phase 2 | Marginal Zone Lymphoma | Dec 2027 |
| The First Affiliated Hospital with Nanjing Medical University | Linperlisib PI3K inhibitor (specifically PI3K alpha inhibitor) | PIK3CA | Phase 2 | Non-Hodgkin Lymphoma | Dec 2027 |
| Faeth Therapeutics | Serabelisib PI3-kinase p110-alpha subunit inhibitor | PIK3CA | Phase 2 | Endometrial Cancer; HR+ HER2- Breast Cancer | Sep 2028 |
| University of California, Los Angeles | Fimepinostat HDAC and PI3K inhibitor | HDAC, PIK3CA | Phase 2 | Cushing Disease | Jan 2029 |
| Haihe Biopharma | CYH33 PIK3CA inhibitor | PIK3CA | Phase 2 | Ovarian Cancer; PIK3CA-Related Overgrowth Spectrum (PROS) | Dec 2029 |
| Restorbio | Dactolisib (BEZ235) Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 2 | Respiratory Tract Infections; Covid19 | – |
| Eli Lilly | LOXO-783 PIK3CA inhibitor | PIK3CA | Phase 1 | Breast Cancer | Dec 2026 |
| Eli Lilly | Samotolisib (LY3023414) Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 1 | Breast Neoplasms; Endometrial Cancer | Dec 2026 |
| Brown University | Copanlisib PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor | PIK3CA, PIK3CD | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Jan 2027 |
| Sovargen | Paxalisib (SVG103) PI3-kinase class I inhibitor | PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2 | Phase 1 | Focal Cortical Dysplasia; Primary Central Nervous System Lymphoma; Glioblastoma; CDK Gene Mutation … | Feb 2027 |
| Yanyan Liu | Linperlisib PI3K inhibitor | PIK3CA | Phase 1 | Peripheral T-cell Lymphoma | May 2027 |
| Ensem Therapeutics | ETX-636 Pan-mutant-selective PI3Kα inhibitor and degrader | PIK3CA | Phase 1 | Advanced Solid Tumors | Jun 2027 |
| Vividion Therapeutics | VVD-159642 RAS-PI3Kα inhibitor | KRAS, PIK3CA | Phase 1 | Advanced Solid Tumors | Aug 2027 |
| The First Hospital of Jilin University | Linperlisib PI3K inhibitor (p110α selective) | PIK3CA | Phase 1 | Lymphoma | Aug 2027 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | BBO-10203 PI3Kα:RAS breaker | PIK3CA, KRAS, NRAS, HRAS | Phase 1 | Non-Small Cell Lung Cancer; Solid Tumor, Adult; Non-small Cell Lung Cancer | Aug 2027 |
| Beijing Tongren Hospital | Linperlisib PI3K inhibitor | PIK3CA | Phase 1 | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Oct 2027 |
| Totus Medicines | TOS-358 Covalent Phosphoinositide-3-Kinase (PI3K)-alpha inhibitor | PIK3CA | Phase 1 | HR+/HER2-negative Breast Cancer | Dec 2027 |
| Regor Pharmaceuticals | RGT-490 PIK3CA inhibitor | PIK3CA | Phase 1 | Breast Cancer | Apr 2028 |
| Changchun GeneScience Pharmaceutical | GenSci145 PIK3CA inhibitor | PIK3CA | Phase 1 | Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated | Nov 2028 |
| Sun Yat-sen University | Linperlisib PI3K-alpha inhibitor | PIK3CA | Phase 1 | Peripheral T-cell Lymphoma; Extranodal Natural Killer/T Cell Lymphoma | Dec 2028 |
| Cogent Biosciences | CGT6297 PIK3CA mutant-selective inhibitor | PIK3CA | Phase 1 | PIK3CA Mutations | Jul 2029 |
| Eli Lilly | STX-478 mutant-selective PI3Kα inhibitor | PIK3CA | Phase 1 | Breast Cancer | Jul 2030 |
| Recursion Pharmaceuticals | REC-7735 PIK3CA-H1047R inhibitor | PIK3CA | Phase 1 | Solid Tumors | Jan 2031 |
| Dana-Farber Cancer Institute | Copanlisib PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor | PIK3CA, PIK3CD | Phase 1 | Diffuse Large B Cell Lymphoma | – |
| Eli Lilly | Tersolisib (LY4064809) PI3K inhibitor | PIK3CA | Phase 1 | Healthy | – |
Breast Cancer (19) Endometrial Cancer (4) Breast Neoplasms (3) PIK3CA-related Overgrowth Spectrum (PROS) (3) Advanced Malignant Solid Neoplasm (3) Advanced Solid Tumors (3) Follicular Lymphoma (3) Advanced Lymphoma (3) Peripheral T-cell Lymphoma (3) Advanced Breast Cancer (2) Insulin Resistance (2) Solid Tumor, Adult (2)
small molecule (32), mixed (7), antibody (1)
Eli Lilly (5) The First Affiliated Hospital of Xiamen University (2) National Cancer Institute (NCI) (2) Novartis (1) Recursion Pharmaceuticals (1) TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (1) Totus Medicines (1) Risen (Suzhou) Pharma Tech (1) iOnctura (1) Institute of Hematology & Blood Diseases Hospital, China (1) Liling Zhang (1) Restorbio (1) Brown University (1) Roche (1) Haihe Biopharma (1) Faeth Therapeutics (1) Beijing Tongren Hospital (1) Peking University (1) MedSIR (1) Regor Pharmaceuticals (1)
PIK3CB (7) PIK3R1 (5) PIK3CG (5) PIK3CD (4) MTOR (3) KRAS (2) PIK3R2 (2) NRAS (1) HRAS (1) PIK3D (1) MAP2K4 (1) HDAC (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.